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Summary.-Monoclonal antibodies to epithelial-cell antigenic determinants, labelled
with 1231 and 1251, were administered parenterally to immunodeficient mice bearing
human tumours derived from a human cancer cell line. Anterior, posterior and lateral
radioscans of the body were taken with a gamma scintillation camera at various
times from immediately to 65 days after injection. Visual displays of the images were
processed by standard computer techniques. The model used a human colon-cancer
cell line, HT29, and the monoclonal antibody, AUA1, which is specific to an epithelial
proliferating antigen. Tumour detection was achieved in all the mice. The smallest
tumour detectable appeared to be about 1 mm in diameter. The degree of antibody
uptake inatumourdepended onits size and the blood supply ofits surrounding tissues
We believe that the technology and skills are now available for accurate radio-
immunodetection of cancer in man.
THE LOCALIZATION OF CANCER in man
using radionuclides has so far been non-
specific, relating, for example, to a focal
defect on a liver scan or a focal area of
increased activity on a bone or a brain
scan. The recognition of tumour-associ-
ated and highly tissue-specific antigens,
the development by Kohler and Milstein
(1975) of the monoclonal-antibody tech-
nique and the regular production by
A.E.R.E. Harwell of pure iodine-123
bring together the requirements for accur-
ate radioimmunodetection of cancer in
man.
Radioimmunodetection of cancer is not
a new field and its potential clinical use
has been demonstrated by many authors
in the past (Korngold & Pressman, 1964;
Mach et al., 1980; Goldenberg et al., 1980;
Begent et al., 1980; Moshakis et al., 1981a).
This study, using a human cancer cell
line in an animal model and a pure 1231-
1
labelled monoclonal antibody, extends
previous results.
METHODS
JMonoclonal antibodies
The monoclonal antibody AUA1 was
obtained from Arklie (1981), who raised it in
the conventional fashion by immunizing
BALB/c mice with the colon-carcinoma cell
line LoVo (Stragard et al., 1980).This antibody
is specific for an epithelial proliferating
antigen as found by testing in binding assays
against epithelial-cancer cell lines and in
sections using immunofluorescent and im-
munoperoxidase techniques and involving
normal and malignant epithelial tissues
(Arklie, 1981). Using immunoperoxidase stain-
ing, this antibody stains positively human
colon carcinomas as well as the villi ofnormal
colon. It is not a tumour-specific antibodv,
but it is tissue-specific and tumour-associated.
The negative-control monoclonal antibody
M236 was obtained from Dr R. Knowles, whoA. A. EPENETOS ET AL.
raised it against the lymphoblastoid cell line
MOLT4. (MinowAadaetal., 1972). Thisantibody
has been found to be specific for cells of the
T-lymphocyte lineage and does not react w%Aith
cells of epithelial origin.
Both antibodies were grown in bulk, either
as ascites in mice or as supernatants in tissue
culture. The average concentration of anti-
bodies -was 2 mg/ml in ascites and 10 Mtg/ml in
supernatant.
Characterizatioit of imim.nunoglobulin
AUA1 and M236 were found to belong to the
IgGi subclass by Ouchterlony double diffu-
sion. (Ouchterlony, 1970).
Preparation ofpure IgG.-Ammonium sulph-
ate precipitation (Kekwick, 1940) w%Aas used as
a first step in separating the bulk of albumin
from the immunoglobulin. The precipitate
was then filtered through a, protein-A-
Sepharose column and the IgGi subfraction
was eluted using a citrate buffer (pH 6 0)
(Ey et al., 1978). The purity of the IgG1 was
checked using polyacrylamide-gel electro-
phoresis (Laemmelli, 1970) and isoelectric
focusing (Awdeh et al., 1968). Both tech-
niques showed a characteristic monoclonal
pattern, indicating a highly purified product.
Binding to cells.-The reactivity of the
fractions containing AUA1 and M236 was
determined by binding to HT29 and MOLT4
cells in a radioimmune binding assay
(Williams, 1977). Both antibodies were
tested for reactivity, and were found to bind
to their respective target cells after inodina-
tion.
Iodination of monoclonal antibodies.-The
IgGI fractions were iodinated with 1231 or 1251
using 2 methods: Chloramine T (Greenwood et
al., 1963) and Jodogen (Salacinski et al., 1980).
Both techniques w%ere similar in efficacy,
yielding about 80% incorporation of iodine
into immunoglobulin when equimolar
amounts of iodine and immunoglobulin were
used in the initial reaction. The chloramine T
method was as follows: 25 ul of antibody at
1 mg/ml in citrate buffer (pH 6.0) mixed with
25 gtl of phosphate buffer (0.3M, pH 7-4) were
reacted with 10 ,ul of1251 (37 MBq,Amersham,
1 mC code 1 IMS 30 and 10 tl ofchloramine T
(2 mg/ml) in phosphate buffer (0-3M, pH 7.4).
The reaction solution was mixed for 2 min.
Free iodine w%ras removed by gel filtration.
using a G50 Sephadex column and eluting
with phosphate-buffered saline (PBSA)
The G50 Sephadex wxas prewashed with
1% BSA in PBSA. The iodogen method was
as follows: 2 ml of iodogen (40 ,ug/ml) in
dichloromethane wAvas allowed to dry in small
conical propylene tubes. Antibody, phosphate
buffer and 125 at the same amounts as used
for the chloramine T method were added and
left for 20 min. Again free iodine was re-
moved using a G50 Sephadex column. In
both techniques a specific activity of 5
mqB,ug was achieved.
When iodinating with 1231 (A.E.R.E.,
Harwell) the conditions were the same as for
1251, except that phosphate buffer (0-3M, pH
5.5) was used to adjust the final pH to 7 4, and
100 ,u of 1231 in 0-04M NaoH (pH 12.4)
equivalent to 37 MBq (]mG) were added.
The iodination efficiency using 1231 was less
then when using 125, probably because 1231 iS
more dilute (it has a molarity of 4x 1O-8M
compared to 125I of 5x 1O-5M). The anti-
bodies were injected into mice on the same
day that they were iodinated.
The different iodine isotopes 1231 and 1251
were used for different purposes. 1231 gives
maximum clarity of tumours at any depth of
tissue. Although it has a half-life ofonly 13 h.
adequate views were obtained up to 96 h
after injection. The principal radiation of
1231 is a y-ray with an energy of 160 keV,
which is ideally suited for present-day
y-cameras.
125 is used to examine the long-term
behaviour of the labelled monoclonal anti-
body in the tumour. Studies with 125 have
been carried out sequentially up to 65 days
from injection ofantibody. 125 also offers the
opportunity for autoradiographs on tumour
masses and other organs.
The monoclonal antibody M236 labelled
with 125 and 1231 was used as a negative
control. A monoclonal antibody of the same
immunoglobulin subclass (IgGi) provides the
most appropriate comparison between specific
and nonspecific uptake. Subtraction of the
2 results (i.e. the M236 from the AUA1)
wNas not found to be necessarv for visualiza-
tion of the tumour.
Immunoperoxidase staining
Formalin-fixed and paraffin-embedded sec-
tions of tumours and other organs were first
dewaxed and then fixed in alcohol. Sections
were tested in triplicate: 1 with the
monoclonal antibody of interest (AUA1), 1
w%rith the negative-control antibody (M236)
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and 1 without antibody to assess the non-
specific background staining (Arklie, 1981).
Autoradiography
The selective localization of injected iodin-
ated monoclonal antibody in tumours, in
contradistinction to the absence from other
normal organs, is demonstrated by auto-
radiography (ARG). Formalin-fixed andpara-
ffin-embedded sections of tumours and other
organs are first dewaxed and then fixed in
alcohol. ARGs were prepared using Ilford K5
fluid emulsion. After drying in air the sections
were exposed for 7-30 days at 4°C. The
sections were then developed, fixed and
stained with haemotoxylin for light micros-
copy.
Scanning
Nineteen nude mice and 1 nude rat were
tested. Before scanning, the animals were
anaesthetized with i.p. pentobarbitone. The
amount of injected radiolabel ranged from
0-08mC (3MBq) to0-3 mC (11 0MBq) forl.231,
andfrom0-1 mC (3-7MBq) to20mC(740MBq)
of1251. The amount ofantibody administered
ranged from 2 jig to 500 ,ug. (500 ,g, equival-
ent to 740 MBq=20 mC was given only once
to a nude rat as a therapeutic attempt). All
the mice were injected with antibody in the
range 2-10 pg. Imaging was performed with
a standard y-camera fitted with a high-
sensitivity collimator. The camera was linked
to a computer with data display. The counts
at different regions ofinterest (i.e. total body,
tumour, blood pool) were then calculated and
expressed as a percentage of the initial
injected amount. For each selected region of
interest, a narrow circumferential region was
used as a background area to allow estimation
of uptake. This technique enables us to
quantitate the uptake ofantibody at different
regions of interest sequentially, and thus get
information both on the uptake of the anti-
body and also on its catabolism and excretion
without having to sacrifice the animal. If, for
example, one counts the activity over a
tumour region and the tumour is then re-
moved and counted using standard scintilla-
tion counting, the same count is obtained on
both occasions. Thus this technique, though
different in offering an opportunity to study
the dynamic behaviour of the radiolabelled
antibody, does not give different counts from
conventional scintillation counting.
RESULTS
Tumour localization was achieved in
all the animals. A typical radioscan is
shown in Fig. 1(a), where a mouse with an
i.m. HT29 tumour (Fogh et al., 1977) on its
leftlegwasscanned at 20 min and 2, 18 and
48 h after an i.v. injection ofAUA1 mono-
clonal antibody labelled with 1231. As
can be seen, after 18 h the tumour is
clearlyvisible. Fig. 1(b) shows scans of the
same mouse after being injected with the
nonspecific antibody M236 labelled with
125J, also scanned at 20 min and 2, 18
and 48 h. The scans taken at 18 and 48 h
show some activity over the tumour
region, calculated to be 1% and 0.1% of
the injected amount, respectively. This
uptake is spurious, because 30% of the
counts arising from AUA1 1231 are picked
up in the 125I channel. However, to some
extent there is nonspecific uptake of
Ig, as demonstrated by other experi-
ments in which tumour-bearing mice
were injected with the nonspecific anti-
body alone. The nonspecific uptake of
antibody will depend on at least 2 factors.
Firstly, tumours may have Fc receptors
and thus be able to capture some Ig if it
is aggregated. Secondly, the vascularity
ofa tumour will influence its blood supply
and also the nonspecific trapping of anti-
body. We have performed similar experi-
ments in other tumour models, using a
trophoblastic cell line (Dosmi) and
neuroblastoma cell line (TR14) and found
that both of these grow as vascular tum-
ours and have much higher uptake of
nonspecific antibodies. In the case of the
trophoblastic cell line Dosmi we found
no difference between nonspecific and
specific antibody uptake. When Dosmi
cells were grown as i.m. tumours, we
obtain 30-40% uptake of the injected
amount of any radiolabelled antibody.
This is probably due to the special pro-
perties of the trophoblast for example,
their large number of Fc-receptor sites
(McNabb et al., 1976). A further point,
related to the first two, is of course the
size of the tumour. Nonspecific uptake
increases proportionately with the size
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FIG. 1.-Radioscans of a mouse with an i.m. HT29 tumour on its left leg taken at 20 min, 2 h, 18 h
and 48 h after injection of monoclonal labelled antibody (a) Specific AUA1 labelled with 1231. Note
clearly visible tumour at 18 h and 48 h. (b) Nonspecific M236 labelled with 1251. Very little activity
is seen over the tumour area and 30% of this is due to the counts, arising from AUA1 labelled with
123I and picked up in the 1251 channel.
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FIG. 2. Graphical display of uptake by total body tumour in mice bearing i.m. and s.c. HT29 tumours.
The circles indicate the uptake of the specific antibody and the triangles the uptake of the
nonspecific antibody. Each point represents 5-11 mice. Error bars show s.e.
of the tumour. We tried to use relatively
small tumours from just palpable to
1 cm diameter. Moreover the HT29 cells
grow as rather avascular and centrally
necrotic tumour masses and this explains
the low uptake of the nonspecific M236
antibody with this model. Fig. 2 shows
the uptake of both specific and non-
specific antibodies. The highest and fastest
specific antibody uptake was seen in the
i.m. tumours, with uptake ranging from
0.5% to 25% of the injected dose (mean
- 60%). This level was reached between
4 and 18 h after injection (see Fig. 2).
The average uptake of the nonspecific
antibody was -0- 15% of the injected dose.
Both the i.p. and s.c. tumours had an
uptake of 0 .5%, but it is interesting to
note that in the i.p. tumours the antibody
localized faster (i.e. within 24 h) while
in the s.c. tumours the uptake was slower,
taking up to 6 days to reach maximum
level. There was no measurable (i.e.
<0.1%) uptake of nonspecific antibody
in the s.c. tumours.
The best pictures are seen after a period
ranging from 4 h to 1 week, depending
again on the site of the tumour. For
example, most of the i.m. tumours were
clearly seen after 18 h, because the uptake
in the tumour, after reaching its peak,
remained relatively high for much longer
than in the rest ofthe body, whence it was
mostly cleared by 18 h, thus leaving a
"hotter" spot in the tumour area. These
results could also be expressed in terms
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FIG. 3.-Section of an HT29 tumour after staining with immunoperoxidase technique and using the
specific monoclonal antibody AUA1. Note the dark brown staining of cells, most marked at the
periphery ofthe tumour and indicating reaction with the antibody.
-Z. ; ~P,
FIG. 4.-ARG ofthe HT29 tumour invading pancreas after administration of the specific monoclonal
antibody AUA1 labelled with iodine 125I. Note the dark outline of the tumour islands, indicating
marked uptake of antibody, in contrast to adjacent uninvolved pancreatic tissue.
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the surrounding stroma, due to non-
specific background uptake. The distri-
bution is further confirmed by ARG on
dissected tumours and other mouse organs.
In Fig. 4 a clear outline of the tumours
can be seen against the normal mouse
tissue. Mouse organs such as liver and
spleen were used as negative controls,
and no ARG evidence of antibody was
found. It is of interest that other workers
(Moshakis et al., 1981b) have obtained a
similar pattern of peripheral staining of
xenografted tumours with radiolabelled
monoclonal antibodies.
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that are positive in vitro to the several
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ion index (Moshakis et al., epithelial-cancer surface antigens.
le ratio of specific antibody Our data extend published results
to nonspecific uptake (1251) (Korngold & Pressman, 1964; Mach et al.,
total body divided by the 1980; Goldenberg et al., 1980; Begent
the blood pool. Fig. 5 dem- et al., 1980) on radioimmunodetection
it the localization index of human cancer in several ways. First,
ie in tumours, but remains it seems clear that the use of monoclonal
Le rest of the body. antibodies gives clearer results than con-
label has been found for ventional polyclonal antisera. The ad-
ys. After this the tumours vantages of monoclonal antibodies are
nd the mice had to be killed. however not realised until they arepurified
y of the tumour masses to minimize the presence ofother proteins,
cl as was that of several whether these be albumin or other
that were invaded by tum- immunoglobulins, in order to avoid non-
toxylin and eosin, as well specific uptake of radiolabel. The tumour
oxidase staining using newly uptake of the radiolabel varied between
ly, were used. Fig. 3 dem- 0.5% and 25% of the injected dose,
specificity of the antibody the upper levels being significantly higher
Dperoxidase technique. Note than in previously reported data (Mach
brown) staining of tumour et al., 1980).
to negative (light blue) Using the described methods of purifi-
use stroma. This is particu- cation, the tumour uptake was enough
at the outer margin of the to make any techniques for tumour site
re it is most active meta- enhancement and visualization (Deland
where it is proliferating. et al., 1980) unnecessary.
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specific for epithelial cell surfaces, so
there is no specific or prolonged uptake
in the blood pool and relatively constant
retention on the tumour surface, a point
that may be significant to the possible
therapeutic use of this technique.
Radiolabelling with 123I is ideally
suited for present-day y-camera use,
because with this isotope the clearest
pictures are seen with the minimum
radiation to the host. This, of course,
will be even more important in the human
situation, where deep seated lesions are
sought, with minimal biohazard from
radiation to patient and staff.
Finally, the combination of monoclonal
antibodies, perhaps administered through
different routes (e.g. i.v. and intra-
lymphatically) may give a more complete
picture of size and site of tumour and its
metastases, however small.
Currently, there exist several mono-
clonal antibodies, e.g. A3 and F3 (Taylor-
Papadimitriou, et al., 1981; Arklie, et al.,
1981) (specific to epithelial tissues and
associated with adenocarcinomas of
breast) that when used in combination
may selectively localize to primary (F3)
and metastatic (A3) breast adenocar-
cinomas. Furthermore, the possibility of
therapy using armed monoclonal anti-
bodies with P-emitting radionuclides,
toxins or drugs should now be explored.
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